| Size | Price | Stock | Qty |
|---|---|---|---|
| 500μg |
|
||
| 1mg | |||
| 5mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
The primary targets of OSW-1 are oxysterol-binding protein (OSBP) and OSBP-related protein 4 (ORP4). OSW-1 acts as a specific antagonist of these proteins, disrupting their function in cellular lipid metabolism and transport. By targeting OSBP/ORP4, the compound affects multiple signaling pathways involved in cancer progression. OSW-1 is also a broad-spectrum inhibitor of enterovirus replication. Its mechanism of action involves the regulation of miRNAs and various signaling pathways.
|
|---|---|
| ln Vitro |
OSW-1 has an anti-proliferative effect on sandwich circles and is less cytotoxic to normal cells. The antiproliferative activity of OSW-1 on SW480 and LoVo sandwich circles, as evidenced by cell viability determined by the CCK8 assay, placed the results in comparison with other clinical anticancer treatments. SW480 and LoVo cell lines are obtained from Dukes stage B non-lymphoma and lymphoma metastatic nodules and represent metastatic and metastatic malignancy, respectively. OSW-1 not only demonstrates extraordinarily powerful anti-cancer action in SW480 and LoVo cell lines, with IC50 at nanomolar doses, and is 10-100 times more effective than other anti-cancer medicines, it is cytotoxic to normal epithelial cells The effect is minimal. These data demonstrate that OSW-1 has a high anti-cancer effect, but has a low cytotoxic effect on normal cells [2].
In vitro, OSW-1 demonstrates extraordinarily powerful anticancer activity in SW480 and LoVo colon carcinoma cell lines, with IC50 values in the nanomolar range. It is 10-100 times more effective than other anticancer medicines. Importantly, OSW-1 exhibits minimal cytotoxicity to normal epithelial cells. The antiproliferative activity of OSW-1 on SW480 and LoVo cells is evidenced by cell viability determined by the CCK8 assay. OSW-1 also has an anti-proliferative effect on sandwich cultures. |
| ln Vivo |
In a nude mouse model implanted with LoVo cells and treated with OSW-1 when tumors became operable, we investigated whether OSW-1 was as effective in vivo. The tumor sizes in the treated mice were, on average, less than those in the control group, according to the results. Significant changes were seen 15–17 days after treatment, and as time went on, the discrepancies grew larger until the animals were killed by the solution. The OSW-1 treated group's tumor weight was considerably lower (P<0.05) than that of the control group. Furthermore, tumors treated with OSW-1 did not show any discernible response. According to these findings, OSW-1 tumors have a noticeable in vivo response and a potent inhibitory effect on blood vessel formation [2].
In vivo, OSW-1 has demonstrated efficacy in a nude mouse model implanted with LoVo colon carcinoma cells. When tumors became operable, mice were treated with OSW-1, and tumor sizes in the treated group were significantly smaller than those in the control group. Significant changes were observed 15-17 days after treatment, and the differences grew larger over time. The tumor weight in the OSW-1 treated group was considerably lower (P<0.05) than that of the control group. OSW-1 also demonstrated a potent inhibitory effect on blood vessel formation. |
| Enzyme Assay |
In vitro receptor binding assays for OSW-1 typically involve measuring its binding affinity to OSBP and ORP4. These assays use purified recombinant proteins or cell lysates expressing the targets, incubated with a labeled ligand or probe. The compound's ability to displace the probe or directly bind to the protein is measured using techniques such as surface plasmon resonance or fluorescence polarization. Functional assays assess the compound's ability to inhibit OSBP/ORP4-mediated cellular functions.
|
| Cell Assay |
Cellular assays for OSW-1 are performed in various cancer cell lines, particularly SW480 and LoVo colon carcinoma cells. Cells are treated with varying concentrations of OSW-1, and cell viability is assessed using the CCK8 assay. The compound's effects on cell proliferation, cell cycle progression, apoptosis, migration, and invasion are also evaluated. These assays are used to characterize the compound's anticancer activity and mechanism of action.
|
| Animal Protocol |
In vivo animal studies with OSW-1 have been performed in a nude mouse xenograft model. Human LoVo colon carcinoma cells are implanted subcutaneously into immunodeficient mice. Once tumors are established and reach a operable size, OSW-1 is administered, and tumor growth is monitored. Tumor weights are measured at the end of the study, and the compound's effects on angiogenesis are evaluated. These studies confirm the compound's in vivo anticancer efficacy.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for OSW-1 are not extensively reported. The compound is a complex steroidal saponin with a high molecular weight. It is typically dissolved in DMSO for in vitro studies. The compound is stable when stored as a powder at -20°C. However, detailed pharmacokinetic parameters such as absorption, distribution, metabolism, excretion, half-life, and bioavailability are not available in the literature for this natural product.
|
| Toxicity/Toxicokinetics |
OSW-1 exhibits minimal cytotoxicity to normal cells, indicating a favorable safety profile. However, comprehensive toxicology data for this compound are not extensively reported. As a potent anticancer agent with activity in the nanomolar range, it may have off-target effects or toxicity at higher concentrations. The compound is classified as a research-use-only chemical and is not intended for human consumption. Specific toxicological data are not reported in the available literature.
|
| References | |
| Additional Infomation |
According to reports, Ornithogalum saundersiae contains [(2S,3R,4S,5R)-2-[(2S,3R,4S,5S)-3-acetoxy-2-[[(3S,8R,9S,10R,13S,14S,16S,17S)-3,17-dihydroxy-10,13-dimethyl-17-[(2S)-6-methyl-3-oxohepane-2-yl]-1,2,3,4,7,8,9,11,12,14,15,16-dodecylhydrocyclopenta[a]phenanthrene-16-yl]oxy]-5-hydroxyoxacyclohexane-4-yl]oxy-4,5-dihydroxyoxacyclohexane-3-yl] 4-methoxybenzoate, and relevant data are available.
OSW-1 is a research-grade natural product not approved for clinical use. Its primary application is as a pharmacological tool for studying the role of OSBP and ORP4 in cancer and lipid metabolism. The compound's potent anticancer activity and low cytotoxicity to normal cells make it a valuable lead compound for anticancer drug discovery. It is used to study the mechanisms of cancer progression, including cell proliferation, apoptosis, migration, invasion, and angiogenesis. |
| Molecular Formula |
C47H68O15
|
|---|---|
| Molecular Weight |
873.03
|
| Exact Mass |
872.456
|
| CAS # |
145075-81-6
|
| PubChem CID |
9854230
|
| Appearance |
White to off-white solid powder
|
| Density |
1.31 g/cm3
|
| Boiling Point |
932.5ºC at 760 mmHg
|
| Flash Point |
267ºC
|
| Vapour Pressure |
0mmHg at 25°C
|
| Index of Refraction |
1.592
|
| LogP |
4.024
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
62
|
| Complexity |
1630
|
| Defined Atom Stereocenter Count |
17
|
| SMILES |
[C@H]1(CC2=CC[C@]3([H])[C@@]([H])([C@]2(CC1)C)CC[C@@]1([C@](O)([C@H](C[C@]13[H])O[C@@]1([H])[C@@H]([C@@H](O[C@@]2([H])[C@@H]([C@H]([C@@H](CO2)O)O)OC(C2C=CC(OC)=CC=2)=O)[C@H](CO1)O)OC(=O)C)[C@H](C)C(=O)CCC(C)C)C)O
|
| InChi Key |
MPXTYZZFIJTPPA-MKQTXCTDSA-N
|
| InChi Code |
InChI=1S/C47H68O15/c1-24(2)8-15-34(50)25(3)47(55)37(21-33-31-14-11-28-20-29(49)16-18-45(28,5)32(31)17-19-46(33,47)6)60-44-41(59-26(4)48)39(36(52)23-58-44)62-43-40(38(53)35(51)22-57-43)61-42(54)27-9-12-30(56-7)13-10-27/h9-13,24-25,29,31-33,35-41,43-44,49,51-53,55H,8,14-23H2,1-7H3/t25-,29+,31-,32+,33+,35-,36+,37+,38+,39+,40-,41-,43+,44+,45+,46+,47-/m1/s1
|
| Chemical Name |
(2S,3R,4S,5R)-2-(((2S,3R,4S,5S)-3-acetoxy-2-(((3S,8R,9S,10R,13S,14S,16S,17S)-3,17-dihydroxy-10,13-dimethyl-17-((S)-6-methyl-3-oxoheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-16-yl)oxy)-5-hydroxytetrahydro-2H-pyran-4-yl)oxy)-4,5-dihydroxytetrahydro-2H-pyran-3-yl
4-methoxybenzoate
|
| Synonyms |
Orsaponin
OSW-1 OSW1OSW 1
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~114.54 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.86 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.86 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.86 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1454 mL | 5.7272 mL | 11.4544 mL | |
| 5 mM | 0.2291 mL | 1.1454 mL | 2.2909 mL | |
| 10 mM | 0.1145 mL | 0.5727 mL | 1.1454 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
